Parkinson’s Disease Clinical Trial Results

Browse clinical trials for Parkinson’s Disease by phase, sponsor and reported results. Data from ClinicalTrials.gov.

• Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Adva
  Phase 3 · Merck Sharp & Dohme LLC · Active, not recruiting · Aug 20, 2025
• Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers
  N/A · Rutgers, The State University of New Jersey · Completed · Jul 29, 2026
• Evaluation of Advanced Imaging and Visualization for Clinical Deep Brain Stimulation
  N/A · Duke University · Completed · Jul 24, 2026
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participan
  Phase 3 · Merck Sharp & Dohme LLC · Completed · Jul 20, 2026
• A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK
  Phase 1 · Merck Sharp & Dohme LLC · Completed · Jul 15, 2026
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Dis
  Phase 2 · Hoffmann-La Roche · Active, not recruiting · Feb 8, 2021
• A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
  Phase 2 · NeuroDerm Ltd. · Completed · Jul 9, 2026
• A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)
  Phase 2 · Integrative Research Laboratories AB · Completed · Jul 9, 2026
• Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metas
  Phase 3 · Merck Sharp & Dohme LLC · Completed · Dec 20, 2023
• Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsq
  Phase 3 · Merck Sharp & Dohme LLC · Completed · Feb 6, 2025
• Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With
  Phase 2 · Merck Sharp & Dohme LLC · Active, not recruiting · Jun 8, 2026
• Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Lin
  Phase 2 · Merck Sharp & Dohme LLC · Completed · Jul 1, 2026
• Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080
  Phase 2 · Merck Sharp & Dohme LLC · Completed · Jun 23, 2026
• KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational A
  Phase 2 · Merck Sharp & Dohme LLC · Completed · May 13, 2026
• Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programm
  Phase 3 · Merck Sharp & Dohme LLC · Completed · Aug 26, 2025

Trials by condition

Lung CancerNon-Small Cell Lung CancerBreast CancerColorectal CancerGastric CancerLiver CancerPancreatic CancerProstate CancerOvarian CancerMelanomaLeukemiaLymphomaMultiple MyelomaGlioblastomaType 2 DiabetesObesityHypertensionHeart FailureAtrial FibrillationStrokeChronic Kidney DiseaseNASH / MASHAlzheimer’s DiseaseParkinson’s DiseaseMultiple SclerosisDepressionEpilepsyALSRheumatoid ArthritisPsoriasisAtopic DermatitisCrohn’s DiseaseUlcerative ColitisLupusAsthmaCOPD

All trials